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The recent report by Jolivet et al highlights the progress being made on Multidrug-resistant (MDR) 
infections [1]. However, this report predates the COVID-19 pandemic and it is unclear what the impact will 
be on MDR infections globally. There are reports of a high use of broad-spectrum antibiotics in the hospital 
setting, recognised as a risk factor for hospital-acquired infections (HAI) with MDR organisms [2-4]. Recent 
data have also pointed to significant rates of hospital-acquired pneumonia (HAP) [2]. High rates of 
admission, shortages of staff and personal protective equipment (PPE) and high acuity patients with 
prolonged lengths of stay in overcrowded facilities may also impact on rates of HAI with MDR pathogens 
[2,3]. Moreover, severe COVID-19, which particularly affects elderly patients with multiple comorbidites, 
may be an important factor in determining changes of colonization pressure [2-4]. Equally, wider recognition 
of the importance of nosocomial infections, with stricter hygiene policies, high use of PPE, and patients 
being cared for in new temporary hospitals, could al  mitigate against this threat [2,3]. We have tried to 
summarise in Table I the potential relative impact of these various factors to provide a conceptual framework 
for determining the overall impact [2-6]. 
Novel cost-effective surveillance programmes of MDR HAI in both high- and low/middle-income countries 
will be even more important in the post COVID-19 era, combined with enhanced stewardship interventions. 
These need to be planned for now, to facilitate future integration with any future pandemic surveillance.  
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Table I. Potential Covid-19 impact on hospital transmission of multidrug-resistant organisms (MDRO)  
 Factors that may favour MDRO 
transmission 
Factors that may prevent MDRO 
transmission 
Infection prevention 
& control practices 
and use of PPE 
Shortage of PPE due to the rapid increase in 
people admitted with SARS-CoV-2  [3-5] 
Isolation of COVID-19 patients, application 
of enhanced standard precaution (hand-
hygiene policy and respiratory hygiene), 
use of PPE (when available), and 




The need for large-scale medical assistance 
exceeds hospital beds availability resulting in 
overcrowded facilities [3,6] 
Lack of beds in ICUs has led to new 
facilities being developed both within and 
outside current hospital ICU settings, many 




High rates of staff sickness and nosocomial 
acquisition of COVID-19 , leading to low 
HCW-to-patient ratio [3,5,6] 
COVID-19 designed ICUs with dedicated 
HCWs may have decrease cross-
transmission of nosocomial infections [3,4] 
Demographic 
features of COVID-
19 affected patients 
Elderly patients with comorbidities require 
prolonged hospitalizations with mechanical 
ventilation support with high use of broad-
spectrum antibiotics administration [2-4] 
Lower rates of admission to hospital from 
long term care facilities may lead to less 
transmission cycles between long term care 
facilities and hospitals  [2-4] 
 
 
 
 
 
 
